NextGen Scientific LLC today issued an updated announcement to correct and replace its previous press release regarding the company's $10 million Regulation D, Rule 506(c) private placement offering to accredited investors. The revised release provides accurate details on the structure and use of proceeds.
The offering involves raising $10 million from accredited investors, with proceeds designated to acquire up to 3.1% ownership in Ionics Life Sciences Limited and its subsidiaries, including Genzada Pharmaceuticals USA and Hyatt Life Sciences. This strategic investment aims to diversify NextGen's portfolio across clinical-stage drug development and revenue-generating nutraceuticals.
Genzada Pharmaceuticals USA, an early-stage biotechnology company, focuses on oncology drug development with two clinical-stage candidates. GZ17-6.02, an oral compound, has shown safety and efficacy in preclinical and clinical studies and is currently under evaluation in a metastatic prostate cancer study at Virginia Commonwealth University. GZ21T, a topical therapy for cancerous and precancerous skin conditions, is expected to receive regulatory approval in Q1 2026 to initiate a Phase 1b/2a clinical trial in actinic keratosis patients in Sweden and the Netherlands. Capital raised will primarily support clinical and preclinical programs for these candidates, along with drug manufacturing and development activities.
Hyatt Life Sciences is a revenue-generating nutraceutical and botanical sciences enterprise specializing in science-based dietary supplements, operating within the rapidly expanding global nutraceuticals market. The investment provides exposure to both high-risk, high-reward drug development and a stable, growing revenue stream.
“During our Phase I dose escalation study for GZ17-6.02, we observed promising biological effect against a broad array of cancer types and we are excited to further explore how this translates into meaningful clinical impact,” said Chief Operating Officer Cameron West, MD, FAAD. “In addition, based on the significant body of preclinical data and the promising preliminary safety profile of GZ21T, I am optimistic that it has the potential to deliver game changing results in a multitude of dermatologic conditions.”
Investors in the offering gain exposure to both clinical-stage drug development and a growing, revenue-generating, science-driven nutritional supplements business. Proceeds will primarily support clinical studies of GZ21T in atopic dermatitis, pre-clinical advancement, and the clinical and pre-clinical development of GZ17-6.02 for prostate and breast cancer, along with drug manufacturing activities and targeted marketing initiatives for the company's supplement portfolio.
NextGen Scientific is a life sciences company focused on advancing oncology and dermatology drug development while participating in the commercialization of science-backed wellness products. Through its strategic investment in Ionics Life Sciences and its subsidiaries, NextGen is building a diversified healthcare platform designed to generate long-term value through clinical innovation and active revenue streams. More information is available at https://investinnextgen.com/.
This communication is not an offer to buy or sell securities; any offerings will be made solely through official offering documents. Forward-looking statements involve risks and uncertainties; the company undertakes no obligation to update them except as required by law.
